Edition:
Deutschland

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

7,152JPY
20 Sep 2019
Change (% chg)

¥26 (+0.36%)
Prev Close
¥7,126
Open
¥7,111
Day's High
¥7,224
Day's Low
¥7,074
Volume
1,909,000
Avg. Vol
1,809,847
52-wk High
¥7,358
52-wk Low
¥3,277

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Buy/Sell

Sell Hold Buy
2.09 Mean rating from 11 analysts

Overall

Beta: 0.97
Market Cap(Mil.): ¥4,410,051.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 1.13

CORRECTED-UPDATE 1-AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

Sept 4 AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.

CORRECTED-UPDATE 1-AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

Aug 9 AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.

CORRECTED-AstraZeneca's Tagrisso gets China OK for type of lung cancer

Sept 4 AstraZeneca Plc said on Wednesday it had received marketing authorisation from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients

* Result a fillip for GSK's comeback bid in oncology (Adds detail on class of drugs, rivals)

UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

Aug 2 The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

Aug 2 The U.S. Food and Drug Administration (FDA) on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor usually affecting joints and limbs.

UPDATE 4-AstraZeneca raises sales forecast after Q2 cancer drug, China boost

* Sees FY product sales growth in low double-digit percentage

UPDATE 1-FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.08%
Rohstoffe -0.55%
Industrie -0.61%
Konjunktur abhängige Waren & Dienstleistungen -0.28%
Konjunktur unabhängige Waren & Dienstleistungen -0.19%
Finanzindustrie +0.60%
Pharma -0.87%
Technologie +0.65%
Telekommunikation +0.19%